Skip to main content

Table 3 Comparison of pooled PCR-uncorrected proportions of adequate clinical and parasitological response between AQ-SP and ACT.

From: Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon

ACT Odds-ratio (95% CI), as compared to AQ-SP
day 2 day 3 day 14 day 28
AM-LM 25.6
(8.21-79.5)*
ND 2.81
(0.28-27.7)
6.32
(1.35-29.6)*
AS-AQ 26.4
(12.4-56.4)*
16.0
(3.35-76.1)*
0.72
(0.20-2.62)
0.80
(0.40-1.61)
AS-CD 34.7
(11.2-107)*
ND 0.26
(0.07-0.96)*
0.35
(0.16-0.75)*
AS-MQ 11.4
(4.76-27.1)*
3.26
(0.84-12.7)
0.36
(0.10-1.41)
1.45
(0.57-3.71)
AS-SP 18.9
(8.64-41.2)*
5.30
(1.57-17.9)*
0.91
(0.22-3.64)
1.34
(0.60-2.93)
DH-PP 37.4
(12.2-115)*
ND 0.80
(0.18-3.50)
9.16
(2.0-42.5)*
  1. Patients who were excluded or lost-to-follow-up were not included in the analysis. Data from a total of 709 patients were analysed, with treatment as a single covariate. Asterisks denote P < 0.05. ND (not done) denotes infinite OR due to 100% ACPR. On day 7, 100% ACPR was observed with all bitherapies. ACT, artemisinin-based combination therapies; AS-AQ, artesunate-amodiaquine; AS-MQ, artesunate-mefloquine; AS-SP, artesunate-sulphadoxine-pyrimethamine; AM-LM, artemether-lumefantrine; AS-CD, artesunate-chlorproguanil-dapsone; DH-PP, dihydroartemisinin-piperaquine; AQ-SP, amodiaquine-sulphadoxine-pyrimethamine.